Blood vessels serve as the intricate network that maintains "life" in the human body and these vessels collectively span 60,000 miles in total length. Particularly, arterial vessels deliver the fresh blood from the heart to the entire body. At VasThera, our mission is clear - to cure chronic vascular disease by reversing the damage that has occurred within the arterial vascular network.
Blood vessels serve as the intricate network that maintains "life" in the human body and these vessels collectively span 60,000 miles in total length. Particularly, arterial vessels deliver the fresh blood from the heart to the entire body. At VasThera, our mission is clear - to cure chronic vascular disease by reversing the damage that has occurred within the arterial vascular network.
For over 20 years, we have dedicated our research to understanding the role of intracellular H2O2 in the receptor-mediated signaling pathway. H2O2 plays a crucial role as a second messenger, and any disruption can lead to abnormal signaling and damage to cells and tissues. Peroxiredoxin (Prx), the key thiol peroxidase enzyme, plays a pivotal role in controlling intracellular H2O2 levels. Therefore, Prx deficiency triggers a surge in intracellular H2O2 levels, disrupting cellular homeostasis.
BackgroundThrough a unique discovery platform called RedoxizymeTM, VasThera establish the chemical library of novel scaffolds that emulate the enzymatic activity of peroxiredoxin (Prx). The abnormal redox signaling due to the inactivation or absence of Prx has been identified as “Peroxiredoxin Deficiency Syndrome (PDS)”, encompassing a range of human diseases, including cardiovascular diseases, cancer, neurodegenerative diseases, and more. Our approach aims to modify abnormal redox signaling with a specific mimetic compound acting as, the Prx nanozyme, replacing the inactive Prx enzyme and thereby normalization of cellular function.
Platform